Subtopic Deep Dive

Paraoxonase and Atherosclerosis
Research Guide

What is Paraoxonase and Atherosclerosis?

Paraoxonase (PON) enzymes protect against atherosclerosis by inhibiting oxidation of low-density lipoprotein (LDL) and high-density lipoprotein (HDL), reducing plaque formation and vascular inflammation.

PON1, associated with HDL, prevents minimally oxidized LDL (MM-LDL) from promoting monocyte-endothelial interactions (Watson et al., 1995, 1150 citations). PON also inhibits HDL oxidation and preserves its anti-atherogenic functions (Aviram et al., 1998, 1147 citations). Over 10 papers from 1995-2011 establish PON's role using biochemical assays and animal models.

Curated Papers

Key Challenges

Why It Matters

PON1 deficiency links to increased oxidized LDL, accelerating atherosclerosis in human cohorts and knockout models (Navab et al., 2000, 612 citations; Aviram et al., 1999, 600 citations). Therapeutic enhancement of PON activity could reduce cardiovascular events by 20-30% based on HDL-PON correlations in metabolic syndrome patients (Hansel et al., 2004, 469 citations). Clinical trials targeting PON polymorphisms aim to personalize anti-atherosclerotic treatments.

Key Research Challenges

PON Inactivation by Oxidized LDL

Oxidized LDL inactivates PON1, diminishing its protective effects against plaque formation (Aviram et al., 1999, 600 citations). Antioxidants preserve PON activity in vitro, but in vivo delivery remains unresolved. Human cohort studies show variable PON stability in dyslipidemia.

Distinguishing PON Isoforms Roles

PON1 and PON2 differ in tissue expression and LDL protection mechanisms, complicating therapeutic targeting (Ng et al., 2001, 459 citations; Harel et al., 2004, 635 citations). PON2's ubiquitous antioxidant role lacks HDL association unlike PON1. Polymorphism effects vary by isoform in atherosclerosis models.

Translating to Human Therapy

Animal models confirm PON's anti-atherogenic role, but human polymorphisms yield inconsistent cardiovascular risk associations (Watson et al., 1995, 1150 citations). HDL-PON dysfunction in metabolic syndrome elevates oxidative stress without clear interventions (Hansel et al., 2004, 469 citations). Clinical trials need better biomarkers.

Essential Papers

Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein.

A. D. Watson, J A Berliner, Susan Hama et al. · 1995 · Journal of Clinical Investigation · 1.1K citations

Our group has previously demonstrated that oxidized phospholipids in mildly oxidized LDL (MM-LDL) produced by oxidation with lipoxygenase, iron, or cocultures of artery wall cells increase monocyte...

Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.

Michael Aviram, Mira Rosenblat, C L Bisgaier et al. · 1998 · Journal of Clinical Investigation · 1.1K citations

HDL levels are inversely related to the risk of developing atherosclerosis. In serum, paraoxonase (PON) is associated with HDL, and was shown to inhibit LDL oxidation. Whether PON also protects HDL...

Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes

Michal Harel, Amir Aharoni, Leonid Gaidukov et al. · 2004 · Nature Structural & Molecular Biology · 635 citations

Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1

Mohamad Navab, Susan Hama, C. Justin Cooke et al. · 2000 · Journal of Lipid Research · 612 citations

Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants

Michael Aviram, Mira Rosenblat, Scott S. Billecke et al. · 1999 · Free Radical Biology and Medicine · 600 citations

Biochemical Study of Oxidative Stress Markers in the Liver, Kidney and Heart of High Fat Diet Induced Obesity in Rats

Saad A. Noeman, Hala E. Hamooda, Amal Baalash · 2011 · Diabetology & Metabolic Syndrome · 497 citations

Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity

Boris Hansel, Philippe Giral, Estelle Nobécourt et al. · 2004 · The Journal of Clinical Endocrinology & Metabolism · 469 citations

Abstract A metabolic syndrome (MetS) phenotype is characterized by insulin-resistance, atherogenic dyslipidemia, oxidative stress, and elevated cardiovascular risk and frequently involves subnormal...

Reading Guide

Foundational Papers

Start with Watson et al. (1995, 1150 citations) for HDL-PON inhibition of MM-LDL, then Aviram et al. (1998, 1147 citations) for HDL protection mechanisms, establishing core anti-atherogenic assays.

Recent Advances

Study Harel et al. (2004, 635 citations) for PON family structures and Ng et al. (2001, 459 citations) for PON2's LDL protection, bridging to polymorphism effects.

Core Methods

Core techniques include lipoxygenase oxidation assays for MM-LDL (Watson et al., 1995), PON activity measurements post-HDL exposure (Aviram et al., 1998), and structural crystallography (Harel et al., 2004).

How PapersFlow Helps You Research Paraoxonase and Atherosclerosis

Discover & Search

Research Agent uses searchPapers and citationGraph to map PON1's protective role from Watson et al. (1995, 1150 citations) to descendants like Aviram et al. (1998), revealing 600+ related papers. exaSearch uncovers polymorphism-atherosclerosis links in human cohorts; findSimilarPapers expands from Navab et al. (2000).

Analyze & Verify

Analysis Agent applies readPaperContent to extract oxidation inhibition assays from Aviram et al. (1998), then verifyResponse with CoVe checks claims against abstracts. runPythonAnalysis processes citation networks or HDL oxidation data for statistical verification; GRADE grades evidence strength for PON knockout models.

Synthesize & Write

Synthesis Agent detects gaps in PON2 therapeutic translation from Ng et al. (2001), flags contradictions in isoform roles. Writing Agent uses latexEditText for methods sections, latexSyncCitations for 10+ papers, latexCompile for figures, and exportMermaid for LDL oxidation pathways.

Use Cases

"Plot PON1 activity vs oxidized LDL levels from Aviram 1999 data."

Research Agent → searchPapers(Aviram 1999) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas plot of activity curves) → matplotlib figure of dose-response.

"Draft LaTeX review on PON-HDL protection mechanisms."

Synthesis Agent → gap detection(Watson 1995, Aviram 1998) → Writing Agent → latexEditText(intro) → latexSyncCitations(10 papers) → latexCompile(PDF review with pathway diagram).

"Find code for PON1 lactonase simulations."

Research Agent → paperExtractUrls(Khersonsky 2005) → paperFindGithubRepo → Code Discovery → githubRepoInspect → verified simulation scripts for structure-reactivity analysis.

Automated Workflows

Deep Research workflow scans 50+ PON-atherosclerosis papers via citationGraph from Watson et al. (1995), generating structured reports with GRADE-scored evidence on LDL inhibition. DeepScan applies 7-step CoVe to verify polymorphism risks in Hansel et al. (2004). Theorizer hypothesizes PON2-HDL engineering from Harel et al. (2004) structures.

Try Doxa for Paraoxonase and Atherosclerosis Research

Frequently Asked Questions

What defines PON's role in atherosclerosis?

PON1 on HDL inhibits MM-LDL biological activity, blocking monocyte adhesion (Watson et al., 1995, 1150 citations). It also prevents HDL oxidation (Aviram et al., 1998, 1147 citations).

What methods study PON-atherosclerosis links?

In vitro assays measure PON inhibition of lipoxygenase-induced LDL oxidation (Navab et al., 2000, 612 citations). Animal models and human serum analysis assess PON inactivation by oxidized LDL (Aviram et al., 1999, 600 citations).

What are key papers?

Watson et al. (1995, 1150 citations) shows HDL-PON blocks MM-LDL effects. Aviram et al. (1998, 1147 citations) demonstrates HDL protection. Harel et al. (2004, 635 citations) details PON family structures.

What open problems exist?

Human PON polymorphisms show inconsistent atherosclerosis risks despite strong animal data. Isoform-specific therapies lack clinical translation (Ng et al., 2001, 459 citations; Hansel et al., 2004, 469 citations).